Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial

Abstract

The glutamate-rich protein (GLURP) of P. falciparum is the target of cytophilic antibodies

which are significantly associated with protection against clinical malaria. A phase 1 clinical

trial was conducted in healthy adult volunteers with the long synthetic peptide (LSP)

GLURP85–213 combined with either Aluminum Hydroxide (Alum, 18 volunteers) or

Montanide ISA 720 (ISA, 18 volunteers) as adjuvants. Immunizations with 10, 30 or 100μg

GLURP85–213 were administered subcutaneously at days 0, 30, and 120. Adverse ...